MedTrace Logo

Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression

NCT00285727 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2008-05-19

No results posted yet for this study

Summary

This is an 8 week study for patients who are currently taking antidepressant medication but not fully responding. Ropinirole CR would be taken in conjunction with current antidepressant medication. Patients come into the clinic once a week when starting on the medication and then once every other week for the remainder of the 8 weeks.

Conditions

  • Depressive Disorder, Major

Interventions

DRUG

Ropinirole CR

Sponsors & Collaborators

Principal Investigators

  • Charles Debattista · Depression Research Clinic, Psychiatry Department, Stanford School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Completion
2007-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00285727 on ClinicalTrials.gov